NCT03500380 2024-02-20A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver MetastasesRemeGen Co., Ltd.Phase 2/3 Unknown301 enrolled